Systematic review and meta-analysis of tirzepatide effects on HbA1c and weight in adults with type 2 diabetesTirzepatide lowers blood sugar and weight in real-world diabetes care

This systematic review and meta-analysis evaluated the efficacy of tirzepatide in adults with type 2 diabetes using data from real-world studies. The analysis included a total sample size of N = 89 296 participants and covered a follow-up period of 3-18 months. The primary outcomes assessed were HbA1c reduction and body weight loss, with secondary outcomes including the percentage of users reaching specific weight loss thresholds.

The pooled results indicated a mean HbA1c reduction of 0.91% with a 95% CI of -1.04 to -0.79. Compared to control, the mean difference in HbA1c reduction was -0.38% (95% CI: -0.44 to -0.33). For body weight, the mean loss was 9.7 kg (95% CI: -14.05 to -5.35), with a mean difference versus control of -6.27 kg (95% CI: -9.22 to -0.33).

Significant proportions of users achieved specific clinical milestones. Sixty-four percent of users reached an HbA1c below 7%. Weight loss outcomes included 47% losing at least 5% of baseline weight, 23% losing at least 10%, 9% losing at least 15%, and 4% losing at least 20%. Safety data, discontinuations, and tolerability were not reported in the source material.

The authors acknowledge moderate to serious bias inherent in the real-world studies used for this analysis. Consequently, the practice relevance is that these observational findings support clinical trial results rather than establishing new causal mechanisms. Clinicians should interpret these results as consistent with existing trial data while recognizing the limitations of the study design.